Pharma News
Fuji Pharma gains rights to darbepoetin alfa biosimilar in Japan
Japan-based Fuji Pharma announced on 5 January 2016 that it had signed a license agreement with Chong Kun Dang Pharmaceutical (CKD Pharma). Under the agreement, Fuji Pharma has the exclusive rights in Japan for the development, manufacture, distribution and sale of CKD Pharma’s darbepoetin alfa biosimilar (CKD‑11101).
Mylan and Momenta to jointly develop and commercialize six biosimilar products
Mylan NV has agreed an exclusive global collaboration with Momenta Pharmaceuticals Inc (Momenta) to develop, manufacture and commercialize six of Momenta's biosimilar candidates.
Eisai acquires Chinese generics maker
Japanese pharmaceutical company Eisai announced on 28 December 2015 that it had acquired Chinese generics maker Liaoning TianYi Biological Pharmaceutical.
Top 10 most read GaBI Online articles in 2015
It has been a hectic year for biosimilars. One of the most important milestones for biosimilars in 2015 was the finalization by the US Food and Drug Administration (FDA) of its regulatory guidelines for biosimilars. Other subjects of interest for biosimilars were the patent expiries of originator biologicals, clinical trials and extrapolation of indications. Biosimilars remain the hot topic for GaBI Online during 2015 and, in fact, all 10 of the most read articles concern biosimilars.
Teva and Takeda partner for generics in Japan
Israeli generics giant Teva Pharmaceutical Industries (Teva) and Japan-based Takeda Pharmaceutical (Takeda) announced on 30 November 2015 that they had made a partnership to provide generics in Japan.
Generic injectable prices stay high even after shortages resolved
Hospitals that have been struggling with shortages and subsequent high prices are now complaining that even after supply gets back to normal prices remain high.
Mylan will not be acquiring Perrigo
Generics company Mylan has failed in its lengthy multi-billion dollar hostile bid to acquire competing generics company Perrigo.
Pfizer cuts some biosimilars after Hospira deal
After completing its US$17 billion acquisition of Hospira, Pfizer is cutting some of its biosimilar collaborations with South Korean drugmaker Celltrion.
Merck Millipore to collaborate with Turkish firm on biosimilars
The Life Science division of Merck, Merck Millipore and Turkish biosimilars start-up Turgut Ilaç are to collaborate on biosimilars.
Teva acquires Mexican drugmaker Rimsa
Israeli generics giant Teva Pharmaceutical Industries (Teva) is expanding its presence in emerging markets with its acquisition of Mexico-based Representaciones e Investigaciones Medicas SA de CV (Rimsa), a specialty drugmaker with a portfolio of products and patents across Latin America.
